According to the Tumor Marker Utility Grading System, uPA and PAI-1 invasion markers along with HER2 are still the most dominant independent novel prognostic factors that have reached the highest level of evidence for clinical utility in BC [4, 147, 148]. Here, ERBB2 is linked to breast cancer.